Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing in Blood and Urine

NCT06339138 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT06339138
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06339138 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing in Blood and Urine
Lead sponsor
Mayo Clinic
Phase
Observational
Overall status
Completed
Start date
June 27, 2018
Completion date
November 12, 2025
Enrollment
589 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chromophobe renal cell carcinoma, clear cell papillary renal tumor, clear cell renal cell carcinoma, kidney oncocytoma, papillary renal cell carcinoma, urothelial carcinoma